Bio-Techne Corporation (tech)
TECH — Company Overview
Bio-Techne Corporation (TECH) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | TECH |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $11.37B |
| Last price | $72.52 |
| Size category | Large Cap |
TECH — Business Description
TECH represents a Biotechnology business in the Healthcare segment. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and auto…
Official website: https://www.bio-techne.com.
TECH — Investment Thesis
At a high level, TECH offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 1.3% year-over-year (public data).
- Trailing P/E of 62.52× implies elevated growth expectations at the current price.
- Forward P/E (31.44×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $11.37B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
TECH — Financial Health
Key financial health indicators for Bio-Techne Corporation are derived exclusively from public data — no proprietary estimates.
Profit margin near 15.0% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $229.65M supports balance-sheet flexibility.
| Trailing P/E | 62.52× |
| Forward P/E | 31.44× |
| Price / Sales | 9.36× |
| Price / Book | 5.37× |
| Gross margin | 66.2% |
| Operating margin | 27.9% |
| Profit margin | 15.0% |
| Return on equity | 9.0% |
| Debt / Equity | 13.71 |
| Free cash flow | $229.65M |
TECH — Growth Outlook
Growth outlook for Bio-Techne Corporation (TECH) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 1.3% suggests steady but measured expansion.
- Price is 0.2% below the 52-week high.
TECH — Competitive Position
Bio-Techne Corporation (TECH) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $11.37B places TECH among large-cap peers.
- Gross margin near 66.2% may reflect pricing power or favorable mix.
TECH — Strengths
Strengths for Bio-Techne Corporation (TECH) inferred from public financial metrics:
- Gross margin of 66.2% supports competitive unit economics.
- Positive free cash flow ($229.65M).
- Moderate leverage (debt/equity 13.71).
- Large Cap scale ($11.37B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
TECH — Weaknesses
Weaknesses and pressure points for Bio-Techne Corporation (TECH) based on available data:
- Elevated trailing P/E (62.52×) limits valuation margin of safety.
TECH — Opportunities
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
TECH — Risks
- Rich valuation (P/E 62.52×) increases downside if growth slows.
TECH — Summary
Bio-Techne Corporation (TECH) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $72.52 with market cap $11.37B. Trailing P/E 62.52×. Revenue grew 1.3% year-over-year per public data. Notable strengths include gross margin of 66.2% supports competitive unit economics. Key watch items include elevated trailing p/e (62.52×) limits valuation margin of safety. Premium Terminal tools for Bio-Techne Corporation add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open TECH in Vest Terminal
Access live data, filings, ownership, and analysis for Bio-Techne Corporation.
Bio-Techne Corporation FAQ
What does Bio-Techne Corporation (TECH) do?
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and…
What is TECH's P/E ratio?
Bio-Techne Corporation has a trailing P/E of 62.52× based on publicly available market data.
Does TECH pay a dividend?
Indicated dividend yield: 0.4%. Confirm ex-dates and payout history in Vest Terminal.
What sector is TECH in?
Bio-Techne Corporation is classified in Healthcare (Biotechnology) on NMS.
What is TECH's market capitalization?
Approximate market cap: $11.37B.
What are the main risks for TECH?
Key risks include above-average volatility (beta 1.27), elevated valuation, among factors on this page.
What are the strengths of TECH?
Potential positives include gross margin of 66.2% supports competitive unit economics, positive free cash flow ($229.65m).
Where can I get analyst estimates for TECH?
Public analyst price targets and consensus for Bio-Techne Corporation are on the free /stocks/tech/estimates page. Deeper estimate history and models are available in Vest Terminal.